Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 59

Sort by

Sort Order Select

Journal Articles

Real World Characteristics and Outcomes of Patients with Relapsed and Refractory Diffuse Large B Cell Lymphoma; A Provincial Experience

Farheen Manji, MD, Douglas A. Stewart, MD FRCPC

Blood (2020) 136 (Supplement 1): 17–18.

https://doi.org/10.1182/blood-2020-139850

Published: 2020

Journal Articles

Clinical Effectiveness of Combination Immunotherapy DPX-Survivac, Low Dose Cyclophosphamide, and Pembrolizumab in Recurrent/Refractory DLBCL: The Spirel Study

Neil L Berinstein, MD, Isabelle Bence-Bruckler, MD, Nicholas Allen Forward, MDMSc,FRCPC, Pierre Laneuville, MD FRCPC, Joy Mangel, MD FRCPC, Douglas A. Stewart, MD FRCPC, Irina Amitai, MD, Gail Klein, MSc, Nancy Pennell, BSc, Iran Rashedi, MD MSc, Kim Roos, BA, BSc, Yogesh Bramhecha, Rebekah Conlon, RN

Blood (2020) 136 (Supplement 1): 16.

https://doi.org/10.1182/blood-2020-136751

Published: 2020

Journal Articles

Generalizability of Landmark Clinical Trials in Diffuse Large B Cell Lymphoma to Real-World Patients: A Single-Centre Retrospective Cohort Study

Marta Davidson, MDPhDFRCPC, Alexandra Rice, MD, Douglas A. Stewart, MD FRCPC, Carolyn Owen, MDFRCPC

Blood (2020) 136 (Supplement 1): 17–18.

https://doi.org/10.1182/blood-2020-137541

Published: 2020

Journal Articles

Plasmablastic Lymphoma: Synergism between Wnt/B-Catenin and the RAS S ignalling Molecules May Identify Potential Targets for Therapy

Hamza Kamran, BSc, Ariz Akhter, PhD, Hassan Rizwan, B.Sc, Meer-Taher Shahbani-Rad, MDFRCPC, Ghaleb Elyamany, MDPhD FRCPC, Douglas A. Stewart, MD FRCPC, Adnan Mansoor, MDFRCPC

Blood (2020) 136 (Supplement 1): 36.

https://doi.org/10.1182/blood-2020-140651

Published: 2020

Journal Articles

Lack of Effectiveness of Intravenous High-Dose Methotrexate for Prevention of CNS Relapse in Patients with High-Risk DLBCL: A Retrospective Analysis from Alberta, Canada

Robert Puckrin, MD, Haidar El Darsa, MD, Sunita Ghosh, PhD P Stat, Anthea Peters, MSc, MD FRCPC, Douglas A. Stewart, MD FRCPC

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-139025

Published: 2020

Journal Articles

Combination of DPX-Survivac, Low Dose Cyclophosphamide, and Pembrolizumab in Recurrent/Refractory DLBCL: The Spirel Study

Neil L Berinstein, MD, Isabelle Bence-Bruckler, MD, Pierre Laneuville, MD FRCPC, Douglas A. Stewart, MD, Nicholas Allen Forward, MDMSc,FRCPC, Liam Smyth, MDFRCPath, Gail Klein, MSc, Nancy Pennell, BSc, Kim Roos, BA, BSc

Blood (2019) 134 (Supplement_1): 3236.

https://doi.org/10.1182/blood-2019-125963

Published: 2019

Journal Articles

Autologous Transplantation As Consolidation for High Risk Aggressive T-Cell Non-Hodgkin's Lymphoma: A SWOG S9704 Intergroup Trial Subgroup Analysis

Blood (2016) 128 (22): 4651.

https://doi.org/10.1182/blood.V128.22.4651.4651

Published: 2016

Journal Articles

Gene-Expression for Prediction of Disease Progression Following Initial Management of Follicular Lymphoma

Etienne Mahe, BSc, MD FRCPC, Ariz Akhter, PhD, Danielle H. Oh, MB ChB, Fahad Farooq, BSc, Meer-Taher Shabani-Rad, MD FRCPC, Adnan Mansoor, MD FRCPC, Douglas A. Stewart, MD FRCPC

Blood (2015) 126 (23): 4804.

https://doi.org/10.1182/blood.V126.23.4804.4804

Published: 2015

Journal Articles

Myeloablative Allogeneic Stem Cell Transplantation in CLL: A Single Centre Retrospective Study

Sonia Cerquozzi, MD FRCPC, Sunita Ghosh, PhD, P.Stat., Diana Quinlan, Amy Trottier, MD, Mary Lynn Savoie, MD FRCPC, Douglas A. Stewart, MD FRCPC, James A. Russell, MD FRCPC, Carolyn Owen, MD MDes (UK), FRCPC

Blood (2015) 126 (23): 5530.

https://doi.org/10.1182/blood.V126.23.5530.5530

Published: 2015

Journal Articles

Population Based Analysis of Outcomes of Primary Central Nervous System Lymphoma (PCNSL) Suggests a Treatment Strategy Including Intensive Chemotherapy with Autologous Stem Cell Transplantation Provides a Survival Advantage for Patients <65 Years of Age

Joanna Graczyk, MD FRCPC, Sunita Ghosh, PhD, Neil Chua, MD FRCPC, Douglas A. Stewart, MD FRCPC, Carolyn J. Owen, MD FRCPC

Blood (2014) 124 (21): 2520.

https://doi.org/10.1182/blood.V124.21.2520.2520

Published: 2014

Journal Articles

Autologous Stem Cell Transplantation Improves Survival for Patients with Follicular Lymphoma in First or Second Relapse: Results of a Comparative Effectiveness Instrumental Variable Analysis

Danielle H. Oh, MB ChB, Qiuli Duan, MSc, Anthea Peters, MD MSc, FRCPC, Neil Chua, MD FRCPC, Douglas A. Stewart, MD FRCPC

Blood (2014) 124 (21): 3972.

https://doi.org/10.1182/blood.V124.21.3972.3972

Published: 2014

Journal Articles

BK Virus Hemorrhagic Cystitis Is Associated with Graft Versus Host Disease and Increased Health Care Resource Utilization in Patients Undergoing Allogeneic Stem Cell Transplantation

Wilson Lam, MD, Jan Storek, MD PhD, Nizar J Bahlis, MD, Christopher Brown, MD, Peter Duggan, MD FRCPC, Michelle Geddes, MD FRCPC, Mary Lynn Savoie, MD FRCPC, Mona Shafey, MD FRCPC, Douglas A. Stewart, MD FRCPC, Andrew Daly, MD FRCPC

Blood (2014) 124 (21): 3901.

https://doi.org/10.1182/blood.V124.21.3901.3901

Published: 2014

Journal Articles

Evaluation Of a Novel 3 Factor Prognostic Score (PS-3) For Patients With Advanced Hodgkin Lymphoma (HL) Treated On US Intergroup E2496

Blood (2013) 122 (21): 4277.

https://doi.org/10.1182/blood.V122.21.4277.4277

Published: 2013

Journal Articles

Outcomes and Correlative Studies Of a Phase I Trial With The Oral PARP1-2 Inhibitor Veliparib In Combination With Bortezomib In Patients With Relapsed Or Refractory Multiple Myeloma

Paola Neri, MD, PhD, Peter Duggan, MD, FRCPC, Kathy Gratton, Li Ren, PhD, Douglas A. Stewart, MD, FRCP, Jonathan J Keats, PhD, Nizar J. Bahlis, MD

Blood (2013) 122 (21): 1978.

https://doi.org/10.1182/blood.V122.21.1978.1978

Published: 2013

Journal Articles

Final Report Of a Phase II Clinical Trial Of Lenalidomide Monotherapy For T-Cell Lymphoma

Ethan Toumishey, B. Sc, Angeli Prasad, CCRP, Gregory S. Dueck, MD, MSc, BSc, FRCPC, Neil Chua, MD, FRCPC, Daygen Finch, MD, Douglas A. Stewart, MD, FRCPC, Darrell J. White, MD, Richard H. van der Jagt, MD, FRCPC, James B Johnston, MD, Andrew R Belch, MD, Tony Reiman, MD

Blood (2013) 122 (21): 4376.

https://doi.org/10.1182/blood.V122.21.4376.4376

Published: 2013

Journal Articles

Presence of Minimal Residual Disease by Flow Cytometry After Induction Chemotherapy Is Less Predictive of Overall and Progression-Free Survival Compared to Conventional Prognostic Factors Including Cytogenetic Risk and Age

Cameron D. Griffiths, MD, Elena Liew, MD, Jennifer K. Grossman, MD, BSc, Douglas A. Stewart, MD, FRCP, Joanne Luider, Iwona Auer, Adnan Mansoor, MD, FRCPC, Michelle Geddes, MD

Blood (2012) 120 (21): 1424.

https://doi.org/10.1182/blood.V120.21.1424.1424

Published: 2012

Journal Articles

Role of Mir-30e in Multiple Myeloma Cells Resistance to Lenalidomide and Bortezomib

Paola Neri, MD, PhD, Kathy Gratton, Li Ren, PhD, Jordan Johnson, Jiri Slaby, MD, Peter Duggan, MD, Douglas A. Stewart, MD, FRCP, Nizar J. Bahlis, MD

Blood (2012) 120 (21): 323.

https://doi.org/10.1182/blood.V120.21.323.323

Published: 2012

Journal Articles

Phase I Study of the PARP1-2 Inhibitor Veliparib in Combination with Bortezomib in Patients with Relapsed or Refractory Multiple Myeloma

Paola Neri, MD, PhD, Peter Duggan, MD, FRCPC, Kathy Gratton, Li Ren, PhD, Jordan Johnson, Jiri Slaby, MD, Douglas A. Stewart, MD, FRCP, Jonathan J Keats, PhD, Nizar J. Bahlis, MD

Blood (2012) 120 (21): 1862.

https://doi.org/10.1182/blood.V120.21.1862.1862

Published: 2012

Journal Articles

Prolonged Survival in Secondary CNS Lymphoma Following High Dose Thiotepa/Busulfan-Based Chemotherapy (HDTB) and Autologous Stem Cell Transplantation (ASCT): Single Institution Results From Calgary, Canada

Lesley E. Street, MD, FRCPC, Nizar J. Bahlis, MD, Karen Valentine, MD, PhD, Deirdre A. Jenkins, MD, FRCPC, Carolyn J Owen, MD, FRCPC, Mona Shafey, MD, FRCPC, Peter Duggan, MD, FRCPC, Douglas A. Stewart, MD, FRCPC

Blood (2012) 120 (21): 2003.

https://doi.org/10.1182/blood.V120.21.2003.2003

Published: 2012

Journal Articles

High Cereblon Protein Expression Correlates with Improved Response and Survival in Myeloma Patients Treated with Lenalidomide

Alexander Klimowicz, PhD, Paola Neri, MD, PhD, Andrew Belch, MD, Michelle Dean, Li Ren, PhD, Kathy Gratton, Jiri Slaby, MD, Jordan Johnson, Peter Duggan, MD, FRCPC, Douglas A. Stewart, MD, FRCPC, Nizar J. Bahlis, MD

Blood (2012) 120 (21): 931.

https://doi.org/10.1182/blood.V120.21.931.931

Published: 2012

NARROW

Real World Characteristics and Outcomes of Patients with Relapsed and Refractory Diffuse Large B Cell Lymphoma; A Provincial Experience

Clinical Effectiveness of Combination Immunotherapy DPX-Survivac, Low Dose Cyclophosphamide, and Pembrolizumab in Recurrent/Refractory DLBCL: The Spirel Study

Generalizability of Landmark Clinical Trials in Diffuse Large B Cell Lymphoma to Real-World Patients: A Single-Centre Retrospective Cohort Study

Plasmablastic Lymphoma: Synergism between Wnt/B-Catenin and the RAS S ignalling Molecules May Identify Potential Targets for Therapy

Lack of Effectiveness of Intravenous High-Dose Methotrexate for Prevention of CNS Relapse in Patients with High-Risk DLBCL: A Retrospective Analysis from Alberta, Canada

Combination of DPX-Survivac, Low Dose Cyclophosphamide, and Pembrolizumab in Recurrent/Refractory DLBCL: The Spirel Study

Autologous Transplantation As Consolidation for High Risk Aggressive T-Cell Non-Hodgkin's Lymphoma: A SWOG S9704 Intergroup Trial Subgroup Analysis

Gene-Expression for Prediction of Disease Progression Following Initial Management of Follicular Lymphoma

Myeloablative Allogeneic Stem Cell Transplantation in CLL: A Single Centre Retrospective Study

Population Based Analysis of Outcomes of Primary Central Nervous System Lymphoma (PCNSL) Suggests a Treatment Strategy Including Intensive Chemotherapy with Autologous Stem Cell Transplantation Provides a Survival Advantage for Patients <65 Years of Age

Autologous Stem Cell Transplantation Improves Survival for Patients with Follicular Lymphoma in First or Second Relapse: Results of a Comparative Effectiveness Instrumental Variable Analysis

BK Virus Hemorrhagic Cystitis Is Associated with Graft Versus Host Disease and Increased Health Care Resource Utilization in Patients Undergoing Allogeneic Stem Cell Transplantation

Evaluation Of a Novel 3 Factor Prognostic Score (PS-3) For Patients With Advanced Hodgkin Lymphoma (HL) Treated On US Intergroup E2496

Outcomes and Correlative Studies Of a Phase I Trial With The Oral PARP1-2 Inhibitor Veliparib In Combination With Bortezomib In Patients With Relapsed Or Refractory Multiple Myeloma

Final Report Of a Phase II Clinical Trial Of Lenalidomide Monotherapy For T-Cell Lymphoma

Presence of Minimal Residual Disease by Flow Cytometry After Induction Chemotherapy Is Less Predictive of Overall and Progression-Free Survival Compared to Conventional Prognostic Factors Including Cytogenetic Risk and Age

Role of Mir-30e in Multiple Myeloma Cells Resistance to Lenalidomide and Bortezomib

Phase I Study of the PARP1-2 Inhibitor Veliparib in Combination with Bortezomib in Patients with Relapsed or Refractory Multiple Myeloma

Prolonged Survival in Secondary CNS Lymphoma Following High Dose Thiotepa/Busulfan-Based Chemotherapy (HDTB) and Autologous Stem Cell Transplantation (ASCT): Single Institution Results From Calgary, Canada

High Cereblon Protein Expression Correlates with Improved Response and Survival in Myeloma Patients Treated with Lenalidomide

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only